![Jonathan Leff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jonathan Leff
Direttore/Membro del Consiglio presso
NorthSea Therapeutics BV
Profilo
Jonathan Leff has over 25 years of clinical development experience in the biotechnology and pharmaceutical industry he focuses on providing his strategic drug development expertise to aid companies from target identification to the market.
He is currently a member of the board of directors for NorthSea.
Prior to joining Sofinnova in 2020, Jonathan served as Senior Vice President and Chief Medical Officer of Ascendis Pharma, a biotechnology company developing medicines for rare endocrine disorders.
Previously Dr. Leff served as Executive Vice President, Research and Development at InterMune (acquired by Roche/Genentech in 2014) where he oversaw the development and US approval of Esbriet® (oral pirfenidone) for the treatment of idiopathic pulmonary fibrosis.
Before InterMune, he was Chief Medical Officer at KaloBios Pharmaceuticals, and Vice President and Chief Medical Officer at Halozyme Therapeutics.
Additionally, Dr. Leff held various positions at Roche, Amgen, and Merck.
Jonathan earned a B.A. in Chemistry from the University of Pennsylvania and received his M.D.
from the University of Pennsylvania School of Medicine.
He completed his medical training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.
Posizioni attive di Jonathan Leff
| Società | Posizione | Inizio |
|---|---|---|
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Investitore di Private Equity | 17/03/2020 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Direttore/Membro del Consiglio | 01/02/2022 |
Precedenti posizioni note di Jonathan Leff
| Società | Posizione | Fine |
|---|---|---|
| AVALYN PHARMA INC. | Direttore/Membro del Consiglio | 01/03/2026 |
| JADE BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/04/2021 |
| ASCENDIS PHARMA A/S | Direttore Tecnico/Scientifico/R&S | 01/10/2019 |
| INTERMUNE INC | Direttore Tecnico/Scientifico/R&S | 31/03/2015 |
| HUMANIGEN, INC. | Vendite & Marketing | 01/02/2012 |
Formazione di Jonathan Leff
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
71
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Humanigen, Inc.
 Humanigen, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in development of cell and gene therapies for treatment of cancers and infectious diseases | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Discovers and develops medicines | Health Technology |
The University of Colorado
 The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Perelman School of Medicine
 Perelman School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Health Technology |
Aerovate Therapeutics, Inc.
 Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
